GUEST POST BY CATE DIAZ, FOUNDER OF MARKET CHEMISTRY 

Kevin invited me to write a piece for CROWDSCALE readers based on what we’re seeing through Market Chemistry, where we've supported over $225M in successful raises across venture capital, angel, and equity crowdfunding rounds. Here it is!

Five years into helping startups raise millions, the biggest lesson I've learned is: Winners show you what's possible and losers show you what's likely. Don’t do yourself a disservice by only studying the winners. 

Out of roughly 6,375 companies that have completed Reg CF or Reg A+ campaigns since 2016, Kingscrowd has tracked 77 positive exits and 186 confirmed failures. Everyone else ends up in the middle. 

Not every crowdfunding deal goes to zero, and the ones that exit can be massive. But pattern recognition matters a lot more than picking any single "home run" deal, and nobody is especially good at predicting which pre-seed startup becomes the next big exit.

What you can get good at is avoiding the obvious losers and building a portfolio that gives the outliers room to work. 

I’ll share what I've learned watching hundreds of raises from the operator side.

First, The J-Curve Reality Retail Investors Miss 

If you invested in your first Reg CF deal in 2022 and your portfolio looks ugly today, you're not doing it wrong. You're reading chapter one of a book that runs eight to twelve chapters long. 

Robert Wiltbank's angel returns research (the dataset everyone cites) shows a pattern: failures appear in the first 2-4 years, while the big winners take 8-12 years to exit. Kingscrowd's exit tracker shows the same shape in Reg CF data, with a median time-to-outcome of 28 months from the first raise. 

Your portfolio will look like it's losing before the winners have a chance to show up. Reg CF only went fully live in 2016, and the majority of deals are still in their early innings.

With that out of the way, here are the Seven Signals We See Across Winners: 

1. Actual revenue at the time of raise. 

Per a decade of SEC Reg CF data analyzed by The Venture Alley, the median Reg CF issuer is a 2-year-old company with 3 employees and less than $10K in revenue. Think about that. 

You're being asked to invest in companies that by definition have almost no commercial traction. Deals with real revenue (and customers) at raise time meaningfully outperform the median. 

Frontier Bio, a startup Kevin featured recently, is a good example of the opposite profile: $5.5M in cumulative sales before asking for a dollar. That doesn't guarantee a return, but it drastically lowers the base rate of failure. 

Revenue at an early stage is particularly meaningful because it tells you the foundation is already built, before the market has priced that in. 

Be aware that well-established growth or later-stage revenue & valuation usually carry a different expected return profile, but more on that below. 

2. Valuation that makes sense for the stage. 

The median Reg CF valuation in 2024 was $15M with an average of $36.5M, per Kingscrowd. A pre-revenue company raising at a $25M cap is asking you to believe a lot. Compare the valuation to real revenue (if any), then compare that multiple to what VCs are paying for similar companies at similar stages in the PitchBook Venture Monitor. 

If the crowdfunding deal is priced higher than what institutional money pays, that should give you pause. 

3. Where you are in the company's funding history. 

This one is underrated. Generation Genius returned 4.07X through a voluntary buyback, but first-round investors got 10.2X.

Atlis Motor Vehicles delivered roughly 10-30X to its earliest Reg CF backers, while later-round investors who bought at the post-IPO price often lost money. 

The earlier you get in, the better the more the final outcome works in your favor. By a company's fourth or fifth crowdfunding round, the valuation has usually crept up enough that the upside is meaningfully capped. 

Later-round deals in established companies can serve a purpose to balance your portfolio as a great way to reduce overall risk, but investors should go in understanding that the return profile looks very different from getting into a revenue-generating company at round one.

4. Founder skin in the game. 

Look at the Form C. Are founders drawing reasonable salaries relative to revenue, or are they paying themselves $300K on $50K of sales? Have they cashed out significant equity before the raise? 

Founders who eat their own cooking tend to build companies that last. 

5. Unit economics that actually work. 

If a company is acquiring customers for $500 and generating $400 of lifetime value, the loop is broken and no amount of capital fixes it. The raise should fund at least 18 months of runway at current burn. 

Campaigns that hide their burn rate or gloss over LTV/CAC are usually hiding it for a reason. 

6. Ability to raise follow-on capital. 

A Reg CF raise is rarely the last money a company will need. The winners almost always graduate to institutional VCs, strategic investors, or larger rounds (such as a Reg A). 

The ones going nowhere get stuck on a Reg CF round after round. If you see a company on its fifth Reg CF raise with little to no change in between, that's something to pay attention to. 

7. Defensible moat, not just a cool product. 

Patents, proprietary data, network effects, regulatory approvals, exclusive partnerships all matter. 

If the only thing standing between the company and a dozen copycats is a nice landing page, the margins will get compressed the moment anyone else notices and duplicates. 

8. (Bonus) Portfolio Math

Early-stage returns follow a power law. That means a very small number of deals drive almost all of the returns, and everyone else either goes to zero or returns 1-2X. There's no getting around this. It's how the asset class works. 

Here's what that looks like in practice. In an analysis of Wefunder's Reg D portfolio, one deal (Zenefits) accounted for roughly 55% of the platform's total gains. Strip out that single company, and the platform IRR drops from 41% to about 12%. 

Now apply that to your own portfolio. 

If you make 3 crowdfunding investments, you're hoping to pick the equivalent of Zenefits in a 3-deal sample. The odds of that working are not the best.

If you make 20 investments, your chances of catching at least one outlier go way up. 

At 50+ investments, you're playing a statistically sound game where the math can actually work in your favor over a long enough time horizon. 

The single most important decision you'll make as a crowdfunding investor has nothing to do with which company you pick first. It's how many positions you're willing to build before you judge the results. If the answer is "fewer than 20," you're playing a game that's hard to win even with perfect selection. 

A Pre-Investment Cheat Sheet 

Before you click invest on any campaign, run it through these questions: 

If you can answer yes to most of these, the deal is worth a closer look. If you're saying no to three or more, walk away no matter how cool the product is. 

Closing Thoughts 

I'll be honest with you: even the best signals won't make early-stage investing safe. Total loss is always possible on any single deal. That's the game. 

But the investors I've watched do well in this space all share the same two traits. 

They're disciplined about which deals they enter, and they're patient enough to let their portfolios play out over 8-12 years instead of 8-12 months. 

Cate Diaz is the founder of Market Chemistry, which helps early and growth-stage startups raise capital through venture, angel, and equity crowdfunding rounds. Market Chemistry has supported over $225M in raises to date. You can find more at mktchemistry.com. Market Chemistry does not provide investment advice to individuals.

Related Reads from CROWDSCALE